Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

詳細情報 詳細情報について

• CRID

  1363388846168461824

• DOI

  10.1016/s1470-2045(10)70233-3

• ISSN

  14702045

• Web Site

  https://api.elsevier.com/content/article/PII:S1470204510702333?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S1470204510702333?httpAccept=text/plain

• データソース種別

  • Crossref